Literature DB >> 2332901

Measurement of progress against cancer. Extramural Committee to Assess Measures of Progress Against Cancer.

.   

Abstract

The questions of the extent of progress against cancer and how to measure it have stimulated attention among scientists and in Congress. In this presentation, we summarize a report requested by the Senate Appropriations Committee to address the adequacy of the existing measures of progress against cancer. The report was prepared by an extramural committee convened by the National Cancer Institute at the request of Congress. It includes extensive findings and recommendations on the existing measures of progress against cancer, the systems used to develop the data reported through the measures, the frequency and content of reports addressing progress, and the need for analytic research on this topic. Although the Extramural Committee To Assess Measures of Progress Against Cancer found the measures and systems to be generally adequate, they also found that modification or expansion of the information base is needed in many areas.

Entities:  

Mesh:

Year:  1990        PMID: 2332901

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  13 in total

1.  A comparative assessment of active surveillance for localized prostate cancer in the community versus tertiary care referral center.

Authors:  Andreas Becker; Daniel Seiler; Maciej Kwiatkowski; Luis Alex Kluth; Dietrich Schnell; Markus Graefen; Thorsten Schlomm; Margit Fisch; Franz Recker; Lothar Weissbach; Felix K H Chun
Journal:  World J Urol       Date:  2014-05-13       Impact factor: 4.226

2.  Assessing progress in reducing the burden of cancer mortality, 1985-2005.

Authors:  Samir Soneji; Hiram Beltrán-Sánchez; Harold C Sox
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

Review 3.  Understanding and communicating risk: Measures of outcome and the magnitude of benefits and harms.

Authors:  Neil R Bell; James A Dickinson; Roland Grad; Harminder Singh; Danielle Kasperavicius; Brett D Thombs
Journal:  Can Fam Physician       Date:  2018-03       Impact factor: 3.275

4. 

Authors:  Neil R Bell; James A Dickinson; Roland Grad; Harminder Singh; Danielle Kasperavicius; Brett D Thombs
Journal:  Can Fam Physician       Date:  2018-03       Impact factor: 3.275

5.  Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for 'healthy drug-user' effect.

Authors:  J Yuen; I Persson; L Bergkvist; R Hoover; C Schairer; H O Adami
Journal:  Cancer Causes Control       Date:  1993-07       Impact factor: 2.506

6.  Assessment of individual organ doses in a realistic human phantom from neutron and gamma stimulated spectroscopy of the breast and liver.

Authors:  Matthew D Belley; William Paul Segars; Anuj J Kapadia
Journal:  Med Phys       Date:  2014-06       Impact factor: 4.071

7.  Annual report to the nation on the status of cancer, part II: Progress toward Healthy People 2020 objectives for 4 common cancers.

Authors:  S Jane Henley; Cheryll C Thomas; Denise Riedel Lewis; Elizabeth M Ward; Farhad Islami; Manxia Wu; Hannah K Weir; Susan Scott; Recinda L Sherman; Jiemin Ma; Betsy A Kohler; Kathleen Cronin; Ahmedin Jemal; Vicki B Benard; Lisa C Richardson
Journal:  Cancer       Date:  2020-03-12       Impact factor: 6.921

Review 8.  Health Disparity and Cancer Health Disparity in China.

Authors:  Qi Wang; Jie Jiao
Journal:  Asia Pac J Oncol Nurs       Date:  2016 Oct-Dec

9.  Five-Year Survival is Not a Useful Measure for Cancer Control in the Population: an Analysis Based on UK Data

Authors:  Si Qi Li; Xiong Fei Pan; Michael Saheb Kashaf; Qing Ping Xue; Hui Jing Luo; Yan Yan Wang; Ying Wen; Chun Xia Yang
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01

10.  On the validity of using increases in 5-year survival rates to measure success in the fight against cancer.

Authors:  Yosef E Maruvka; Min Tang; Franziska Michor
Journal:  PLoS One       Date:  2014-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.